Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo

European Journal of Pharmacology

Volumn 640, Issue 1-3, 2010, Pages 168-171

  Maeda, Akimitsu ^a   Tsuruoka, Shuichi ^a,d   Ushijima, Kentarou ^a   Kanai, Yoshikatsu ^b   Endou, Hitoshi ^c   Saito, Kazuyuki ^e   Miyamoto, Etsuko ^e   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e HOKURIKU UNIVERSITY   (Japan)

Author keywords

Celecoxib; Methotrexate; Organic anion transporter; Pharmacokinetic interaction; Tubular secretion

Indexed keywords

CELECOXIB; LOXOPROFEN; METHOTREXATE; ORGANIC ANION TRANSPORTER 3; PARACETAMOL; SULINDAC; ORGANIC ANION TRANSPORTER; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG UPTAKE; DRUG URINE LEVEL; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION; ANIMAL; BLOOD; CELL LINE; CYTOLOGY; DRUG INTERACTION; GENETICS; KIDNEY PROXIMAL TUBULE; METABOLISM; URINE; WISTAR RAT;

ANIMALS; CELL LINE; DRUG INTERACTIONS; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; METHOTREXATE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; TRANSFECTION;

EID: 77953812855     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.051     Document Type: Article

References (28)

1. Ahern M., Booth J., Loxton A., McCarthy P., Meffin P., Kevat S. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?. J. Rheumatol. 1988, 15:1356-1360.
2. Brouwers J., de Smet P. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1994, 27:462-485.
3. Cha S.H., Sekine T., Fukushima J.I., Kanai Y., Kobayashi Y., Goya T., Endou H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 2001, 59(5):1277-1286.
4. Daly H., Boyle J., Roberts C., Scott G. Interaction between methotrexate and non-steroidal anti-inflammatory drugs. Lancet 1986, 8480:557.
5. EI-Sheikh A., van den Heuvel J., Koenderink J., Russel F. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 2007, 320:229-235.
6. Frenia M., Long K. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann. Pharmacother. 1992, 26:234-237.
7. Hasegawa M., Kusuhara H., Sugiyama D., Ito K., Ueda S., Endou H., Sugiyama Y. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther. 2002, 300(3):746-753.
8. He Y., Tanigawara Y., Yasuhara M., Hori R. Effect of folinic acid on tissue residence and excretion of methotrexate in rats. Drug Metab. Dispos. 1991, 19:729-734.
9. Jayasagar G., Kumar M., Chandrasekhar K., Prasad P., Rao Y. Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. Pharmazie 2002, 57:619-621.
10. Karim A., Tolbert D., Hunt T., Hubbard R., Harper K., Geis G. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol. 1999, 26:2539-2543.
11. Maeda A., Tsuruoka S., Kanai Y., Endou H., Saito K., Miyamoto E., Fujimura A. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur. J. Pharmacol. 2008, 31:166-172.
12. Masada S., Saito H., Inui K. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. J. Pharmacol. Exp. Ther. 1997, 283:1039-1042.
13. Matsumoto S., Yoshida K., Ishiguro N., Maeda T., Tamai I. Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. J. Phamacol. Exp. Ther. 2007, 322:1246-1252.
14. Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., Fukatsu A., Ogawa O., Inui K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 2002, 13:866-874.
15. Murray M., Brater D. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993, 33:435-465.
16. Nozaki Y., Kusuhara H., Kondo T., Iwaki M., Shiroyanagi Y., Nakayama H., Horita S., Nakazawa H., Okano T., Sugiyama Y. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Phamacol. Exp. Ther. 2007, 322:1162-1170.
17. Paulson S., Kaprak T., Gresk C., Fast D., Baratta M., Burton E., Breau A., Karim A. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm. Drug Dispos. 1999, 20:293-299.
18. Paulson S.K., Zhang J.Y., Breau A.P., Hribar J.D., Liu N.W., Jessen S.M., Lawal Y.M., Cogburn J.N., Gresk C.J., Markos C.S., Maziasz T.J., Schoenhard G.L., Burton E.G. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab. Dispos. 2000, 28(5):514-521.
19. Penning T., Talley J., Bertenshaw S., Carter J., Collins P., Docter S., Graneto M., Lee L., Malecha J., Miyashiro J., Rogers R., Rogier D., Yu S., Anderson G., Burton E., Cogburn J., Gregory S., Koboldt C., Perkins W., Seibert K., Veenhuizen A., Zhang Y., Isakson P. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40:1347-1365.
20. Shibayama Y., Ushinohama K., Ikeda R., Yoshikawa Y., Motoya T., Takeda Y., Yamada K. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 2006, 97:1260-1266.
21. Takeda M., Khamdang S., Narikawa S., Kimura H., Hosoyamada M., Cha S., Sekine T., Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Phamacol. Exp. Ther. 2002, 302:666-671.
22. Takeda M., Narikawa S., Hosoyamada M., Cha S., Sekine T., Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur. J. Pharmacol. 2001, 419:113-120.
23. Takeuchi A., Masuda S., Saito H., Doi T., Inui K. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidey Int. 2001, 60:1058-1068.
24. Tracy T., Krohn K., Jones D., Bradley J., Hall S., Brater D. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol. 1992, 42:121-125.
25. Tuyss A., Milano G., Kubar J., Namer M., Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986, 8475:256-258.
26. Uwai Y., Saito H., Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur. J. Pharmacol. 2000, 409:31-36.
27. Uwai Y., Taniguchi R., Motohashi H., Saito H., Okuda M., Inui K. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet. 2004, 19:369-374.
28. Van Aubel R., Masereeuw R., Russel F. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 2000, 279:F216-F232.